[Treatment strategy for untreated transplantation-ineligible multiple myeloma patients]

Area of Science:

• Hematology
• Geriatric Medicine
• Oncology

Background:

• Novel drugs like proteasome inhibitors, immunomodulators, and antibody therapies have advanced multiple myeloma treatment.
• Approved standard regimens exist for elderly multiple myeloma patients ineligible for autologous transplantation.
• Elderly patients exhibit greater clinical diversity (cognitive, mental, social, physical, organ functions) than younger patients.

Purpose of the Study:

• To highlight the challenges of a one-size-fits-all treatment approach for elderly multiple myeloma patients.
• To emphasize the importance of objective geriatric assessments, including organ function and frailty evaluation.
• To advocate for personalized treatment planning considering individual patient diversity and tumor-specific factors.

Main Methods:

• Review of current treatment strategies for elderly multiple myeloma patients.
• Emphasis on geriatric assessment methodologies for evaluating organ function and frailty.
• Consideration of tumor-related factors, including chromosomal abnormalities.

Main Results:

• Standard treatment regimens may not be suitable for all elderly patients due to their diverse clinical profiles.
• Geriatric assessments provide objective measures to understand patient diversity.
• Incorporating tumor characteristics, such as chromosomal abnormalities, is vital for treatment selection.

Conclusions:

• A personalized approach is essential for treating elderly multiple myeloma patients.
• Comprehensive geriatric assessments are critical for tailoring treatment plans.
• Integrating patient-specific and tumor-specific factors optimizes therapeutic outcomes in this population.